MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Edwards Lifesciences Q2 results are better than expected

Edwards Lifesciences Q2 results are better than expected

By

Edwards LifesciencesEdwards Lifesciences (NYSE:EW) stock has jumped in after-hours trading after the company reported Street-beating Q2 results and boosted it earnings outlook.

The Irvine, Calif.–based artificial heart valves and hemodynamic monitoring company reported a loss of –$122 million, or –20¢ per share, off $925 million in revenue during the quarter ended June 30. For the same quarter a year ago — before the COVID-19 pandemic — Edwards saw profits of $242 million, or 38¢ per share, off $1.087 billion in revenue.

Sales of TAVR — a hot area in medtech — took a 12% hit.

The results, though, beat predictions. Adjusted to exclude one-time items, earnings per share were 34¢, double the expectations of The Street, where analysts were looking for EPS of 17¢ on sales of $797.5 million.

Healthcare providers have been working to ensure the safety of people without COVID-19 who are coming in for care, but Edwards Lifesciences has still seen cases of people holding off on heart valve replacement because they are worried about catching the virus. “Irrespective of the unpredictable surges of this deadly pandemic, there is growing recognition that valve therapy should not be postponed as these patients have an urgent need,” CEO Michael A. Mussallem said today in the earnings news release.

Edwards Lifesciences is boosting its adjusted 2020 EPS guidance to $1.75–$1.95, from a previous $1.58–$1.75, while keeping it’s top-line outlook at $4.0–$4.5 billion.

Investors reacted by sending EW shares up 5.6% to $81.61 apiece in after-hours trading. The rise comes after a day that saw Edwards stocks and the overall markets — as well as the MassDevice’s MedTech 100 Index,  which includes stocks of the world’s largest medical device companies — decline as investors unloaded Apple and Microsoft stocks and the U.S. Labor Departement reported a rise in initial jobless benefit claims.

In case you missed it

RSS From Medical Design & Outsourcing

  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]
  • New method of cardiac ablation used in first in-human trial for ventricular tachycardia
    A new cardiac ablation technique for patients with ventricular tachycardia (VT) has been used in its first in-human multicenter trial involving Mayo Clinic. The new process — needle ablation using in-catheter, heated, saline-enhanced, radio frequency (SERF) energy — creates lesion scars inside the heart muscle where life-threatening arrhythmias cause VT, Mayo Clinic said. Injecting heated saline… […]
  • AdvaMed pushes CMS for proposed TCET pathway rule this year
    The Advanced Medical Technology Association (AdvaMed) is asking the Centers for Medicare & Medicaid Services (CMS) to move fast on a new way to guarantee reimbursement for new medtech innovations. CMS repealed the Medicare Coverage of Innovative Technology (MCIT) program last year but promised to explore other options to improve the coverage process for access… […]